Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and Hepatitis B e Antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4121-4128

  Li, Guo Jun ^a   Yu, Yi Qi ^b   Chen, Shao Long ^b   Fan, Ping ^c   Shao, Ling Yun ^b   Chen, Jia Zhen ^b   Li, Chang Shui ^a   Yi, Bin ^a   Chen, Wei Cun ^a   Xie, Shu Yuan ^a   Mao, Xiao Na ^a   Zou, He Hui ^a   Zhang, Wen Hong ^b,d  

^a Second Hospital of Yinzhou of Ningbo   (China)

^b FUDAN UNIVERSITY   (China)

^c Department No 411   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; GUANINE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS B; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOASSAY; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; ENDPOINT DETERMINATION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEROCONVERSION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84935878242     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00249-15     Document Type: Article

References (25)

1. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97-107. http://dx.doi.org/10.1046/j.1365-2893.2003.00487.x.
2. European Association for the Study of Liver Disease. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167-185. http://dx.doi.org/10.1016/j.jhep.2012.02.010.
3. Liaw YF. 2013. Impact of therapy on the outcome of chronic hepatitis B. Liver Int 33(Suppl 1):111-115. http://dx.doi.org/10.1111/liv.12057.
4. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. 2005. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682-2695. http://dx.doi.org/10.1056/NEJMoa043470.
5. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123-129. http://dx.doi.org/10 .1016/S0140-6736(05)17701-0.
6. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662. http://dx.doi.org/10.1002/hep.23190.
7. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C. 2012. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143: 963-973.e9. http://dx.doi.org/10.1053/j.gastro.2012.07.014.
8. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. 2013. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 58: 225-233. http://dx.doi.org/10.1016/j.jhep.2012.09.029.
9. Thimme R, Dandri M. 2013. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 58:205-209. http://dx.doi.org/10.1016/j .jhep.2012.11.007.
10. Sonneveld MJ, Janssen HL. 2011. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int 31(Suppl 1):S78-S84. http://dx.doi.org/10.1111/j.1478-3231.2010.02384.x.
11. Kwon H, Lok AS. 2011. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8:275-284. http://dx.doi.org/10.1038/nrgastro.2011.33.
12. Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM. 2013. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 58:676-683. http://dx.doi.org/10.1016/j.jhep.2012.11.039.
13. Sonneveld MJ, Janssen HL. 2010. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 9:91-98. http://dx.doi.org/10.1007/s11901-010-0041-7.
14. Enomoto M, Tamori A, Nishiguchi S, Kawada N. 2013. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol 48:999-1005. http://dx.doi .org/10.1007/s00535-012-0742-5.
15. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. 2014. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 61:777-784. http://dx.doi.org/10.1016/j.jhep.2014.05.044.
16. Chen S, Zhang W. 2015. HBeAg-positive chronic hepatitis B patients with prior long-time exposure to nucleos(t)ide analogues: "switch-to" or "add-on" PegIFN alfa, that is the question. J Hepatol 62:239. http://dx.doi.org /10.1016/j.jhep.2014.08.056.
17. Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M. 2012. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 54:93-95. http://dx.doi.org /10.1016/j.jcv.2012.01.024.
18. Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P. 2013. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAgnegative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol 58:713-717. http://dx.doi.org/10.1016/j .jcv.2013.09.020.
19. Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu A, Wang JY, Idilman R, Reesink H, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders J, Verhey E, Hansen B, Janssen HL. 2015. Adding peginterferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology 61:1512-1522. http://dx.doi.org/10.1002/hep.27586.
20. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, Cavallone D, Bonino F. 2010. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139:483-490. http://dx.doi.org/10.1053/j.gastro.2010.04.052.
21. Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. 2013. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 59:709-716. http://dx .doi.org/10.1016/j.jhep.2013.06.007.
22. Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. 2013. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 58:923-931. http://dx.doi.org /10.1002/hep.26376.
23. Janssen HL, Sonneveld MJ, Brunetto MR. 2012. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 61:641-645. http://dx.doi.org/10.1136/gutjnl-2011-301096.
24. Liaw YF. 2011. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 54:E1-E9. http: //dx.doi.org/10.1002/hep.24473.
25. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL. 2013. Responseguided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 58: 872-880. http://dx.doi.org/10.1002/hep.26436.